Singapore’s wealth fund GIC agreed to invest around 1 billion dollars in Biomat, a U.S.-based plasma collection company owned by Grifols, thus becoming a strategic investor in the Spanish pharmaceutical company, Grifols said on Wednesday.
GIC will have a minority stake in Biomat USA, which has a network of 296 plasma collection centres in the United States through the acquisition of newly issued non-voting shares.
The company didn’t disclose the stake GIC will taking in Biomat.
Barcelona-based Grifols will use proceedings to reduce debt, which at the end of March stood at 6.2 billion euros ($7.38 billion).
Grifols shares were up 1.5% in early trading, while benchmark Ibex-35 was down 0.7. The company is valued by the market at 13.5 billion euros.
Source: Reuters
Can’t stop reading? Read more
Blackstone taps bond market as private credit BDCs end issuance drought
Blackstone taps bond market as private credit BDCs end issuance drought Blackstone's private...
EQT raises the stakes with revised $12.3bn bid for Intertek
EQT raises the stakes with revised $12.3bn bid for Intertek EQT has tabled an improved takeover...
Temasek’s Azalea bets on evergreen structure to democratise private equity access
Temasek's Azalea bets on evergreen structure to democratise private equity access Azalea, a unit...